Pharmacologic Treatment of Drug Resistant Hypercholesterolemia

<p>Seth M. Kriha, PharmD identifies guideline recommended treatment to reduce LDL-C, evaluates landmark clinical trials for novel therapeutic agents indicated for treatment resistant hypercholesterolemia and develops a pharmacologic care plan for a patient with treatment resistant hypercholesterolemia.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>